Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation...
Hyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"
Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). Clinical safety confirmed through COVID-19 and Dengue clinical trials. Class-wide efficacy proven by accumulated research data for...
Tuniu Discloses Cash Dividend to Holders of ADSs
NANJING, China, April 23, 2026 /PRNewswire/ -- Tuniu Corporation (NASDAQ: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today disclosed that the cash dividend of US$1.197 per American depositary shares ("ADSs")...
Coway Discloses Implementation Assessment of Its Corporate Value-Up Plan
Since announcing its Corporate Value-Up Plan in 2025, Coway has been seeing tangible progress across revenue growth, shareholder returns, financial soundness and governance To date, the company has executed KRW 247.3 billion in shareholder returns,...
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key...